Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03891784 |
|
Recruitment Status :
Recruiting
First Posted : March 27, 2019
Last Update Posted : January 26, 2023
|
Sponsor:
University of Washington
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
University of Washington
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | September 30, 2023 |
| Estimated Study Completion Date : | September 30, 2024 |